Levosimendan administration had no effect on perioperative NT-proBNP and cTnI levels and 2-year all-cause mortality, However, it reduced in-hospital major adverse cardiac events (MACE) and 2-year stroke or HF-related hospitalization. This evidence concerns the gene TNNI3 and hydrops fetalis.